Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)

NCT05440864 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05440864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05440864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
October 26, 2023
Completion date
November 30, 2026
Enrollment
28 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma